GigaGen Secures U.S. BARDA Contract to Develop Antibody Therapies for Botulinum Neurotoxins and Biothreats
GigaGen Inc., a biotechnology firm specializing in innovative antibody treatments for immunodeficiencies, infectious diseases, and cancers resistant to checkpoint inhibitors, has announced a new contract awarded by the Biomedical Advanced Research and Development Authority (BARDA). BARDA, part of the U.S.…